In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers - PubMed (original) (raw)
In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers
K Benlagha et al. J Exp Med. 2000.
Abstract
The CD1 family of major histocompatibility complex (MHC)-like molecules specializes in presenting lipid and glycolipid antigens to alpha/beta T lymphocytes, but little is known about the size of the CD1-restricted T cell population or the frequency of T lymphocytes specific for a given glycolipid antigen. Here, we report the generation and use of mouse CD1d1-glycolipid tetramers to visualize CD1d-restricted T cells. In contrast with previous BIAcore-based estimates of very short half-lives for CD1d-glycolipid complexes, we found that the dissociation rate of several different CD1d-glycolipid complexes was very slow. Fluorescent tetramers of mouse CD1d1 complexed with alpha-galactosylceramide (alphaGalCer), the antigen recognized by mouse Valpha14-Jalpha281/Vbeta8 and human Valpha24-JalphaQ/Vbeta11 natural killer T (NKT) cell T cell receptors (TCRs), allowed us for the first time to accurately describe, based on TCR specificity, the entire population of NKT cells in vivo and to identify a previously unrecognized population of NK1.1-negative "NKT" cells, which expressed a different pattern of integrins. In contrast, natural killer (NK) cells failed to bind the tetramers either empty or loaded with alphaGalCer, suggesting the absence of a CD1d-specific, antigen-nonspecific NK receptor. Mouse CD1d1-alphaGalCer tetramers also stained human NKT cells, indicating that they will be useful for probing a range of mouse and human conditions such as insulin-dependent diabetes mellitus, tumor rejection, and infectious diseases where NKT cells play an important role.
Figures
Figure 1
Long life span of CD1d1–glycolipid complexes. (A) Plate-bound CD1d1 (2.5 μg/ml) was loaded with 0.1 or 0.3 μM αGalCer for 2 h, washed, and chased for different periods of time before adding the Vα14-Jα281 NKT cell hybridoma DN32D3 and measuring IL-2 release in the supernatant (mean ± SD). (B) Plate-bound CD1d1 was first incubated with 30 μg/ml of LAM or GM1 for 6 h, washed, and chased for different periods of time. 0.1 μM αGalCer was added for 2 h and washed before incubation with DN32D3. (C) Microwells were coated overnight with 2.5 μg/ml CD1d1 or BSA or 0.1μM αGalCer, washed, then pulsed for 2 h with 0.1 μM αGalCer as indicated, and washed again before adding the CD1d-restricted Vα14 hybridomas DN32D3 or a control CD1d-restricted non-Vα14 hybridoma, 431.A11 (Vα3.2-Jα8/Vβ8), and measuring IL-2 release (mean ± SD). 431A11 and DN32D3 produced similar amounts of IL-2 when stimulated with CD1d1-expressing thymocytes.
Figure 1
Long life span of CD1d1–glycolipid complexes. (A) Plate-bound CD1d1 (2.5 μg/ml) was loaded with 0.1 or 0.3 μM αGalCer for 2 h, washed, and chased for different periods of time before adding the Vα14-Jα281 NKT cell hybridoma DN32D3 and measuring IL-2 release in the supernatant (mean ± SD). (B) Plate-bound CD1d1 was first incubated with 30 μg/ml of LAM or GM1 for 6 h, washed, and chased for different periods of time. 0.1 μM αGalCer was added for 2 h and washed before incubation with DN32D3. (C) Microwells were coated overnight with 2.5 μg/ml CD1d1 or BSA or 0.1μM αGalCer, washed, then pulsed for 2 h with 0.1 μM αGalCer as indicated, and washed again before adding the CD1d-restricted Vα14 hybridomas DN32D3 or a control CD1d-restricted non-Vα14 hybridoma, 431.A11 (Vα3.2-Jα8/Vβ8), and measuring IL-2 release (mean ± SD). 431A11 and DN32D3 produced similar amounts of IL-2 when stimulated with CD1d1-expressing thymocytes.
Figure 2
Binding of CD1d1–αGalCer complexes to a Vα14-Jα281/Vβ8 NKT cell hybridoma. (A) Biotinylated monomers, revealed with streptavidin-PE. (B) Streptavidin-PE tetramers. (C) Binding curve of CD1d1 tetramers loaded at different concentrations of αGalCer; binding was measured by flow cytometry analysis (mean fluorescence intensity, MFI). Hill Coeff., Hill coefficient (see Materials and Methods).
Figure 4
CD1d1–αGalCer tetramers stained CD1d1-restricted Vα14-Jα281 NKT cells in vivo. (A) Spleen cells from wild-type, CD1d-deficient, or Vα14-Jα281 TCR α chain transgenic mice in a C57BL/6 background were stained with CD1d1–αGalCer tetramers-PE, CD5-Cychrome, and anti–I-Ab–FITC. Dot plots were gated on MHC class II− splenocytes. (B) Splenocytes from normal mice and Vα14-Jα281 TCR α chain transgenics were stained with tetramer-Cychrome, CD5-APC, and anti-CD4 or CD8-FITC. Histograms display the frequency of CD4+ and/or CD8+ cells among gated CD5+ tetramer+ splenocytes.
Figure 3
CD1d1–αGalCer tetramers specifically stained Vα14-Jα281 NKT cell hybridomas. “Empty” or αGalCer-loaded tetramers and anti–TCR-β mAb were used to stain two canonical Vα14-expressing, αGalCer-responsive hybridomas (DN32D3 and 431G5), one CD1d1-restricted αGalCer-unresponsive Vα3.2 hybridoma (431A11), and one Kb-restricted Vα2 hybridoma (RF33.70).
Figure 5
CD1d1–αGalCer tetramer+ cells exhibit intermediate levels of surface TCR and a bias in Vβ usage. Splenocytes from normal mice (top) and Vα14-Jα281 TCR α chain transgenics in a C57BL/6.TCR Cα2/− background (bottom) were stained with tetramer-Cychrome, CD5-APC, and anti-Vβ–FITC. Histograms display the frequency of Vβ1 cells among CD5+ tetramer+ and CD5+ tetramer− splenocytes gated as indicated.
Figure 6
A subset of CD1d1–αGalCer tetramer+ cells are NK1.1− and express upregulated levels of CD49d. Liver lymphocytes from normal C57BL/6 mice were stained with tetramer-Cychrome, NK1.1-PE, and anti-Vβ–FITC or CD49d-FITC. Note that most tetramer+ NK1.1+ cells were CD49d− whereas tetramer+ NK1.1− cells were CD49d+. Both subsets exhibited the same bias in Vβ8 (middle) and Vβ7 and Vβ2 (not shown). Similar results were found for splenocytes and in Vα14-Jα281 TCR α chain transgenic mice.
Figure 7
Mouse CD1d1–αGalCer tetramers stain human Vα24/Vβ11 NKT cells. Human PBLs were stimulated with 0.1 μM αGalCer in vitro and stained after 7 d in culture. In this experiment, CD1d1-mediated αGalCer presentation to NKT cells is provided by the PBLs themselves. After centrifugation through Ficoll, the cells were preincubated with anti-TCR antibodies for 1 h before adding tetramer-PE. Note that anti-Vα24 completely blocks tetramer binding.
Figure 8
CD1d1–αGalCer tetramers do not stain NK cells. Fresh splenocytes (A) or spleen-derived A-LAK cells (B) were stained with CD5-APC, NK1.1-PE, tetramer-Cychrome, and TCR-β–FITC. Less than 1% of NK cells (α/β sTCR−NK1.1+) were tetramer+.
Similar articles
- A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
Hameg A, Apostolou I, Leite-De-Moraes M, Gombert JM, Garcia C, Koezuka Y, Bach JF, Herbelin A. Hameg A, et al. J Immunol. 2000 Nov 1;165(9):4917-26. doi: 10.4049/jimmunol.165.9.4917. J Immunol. 2000. PMID: 11046017 - The complementarity determining region 2 of BV8S2 (V beta 8.2) contributes to antigen recognition by rat invariant NKT cell TCR.
Pyz E, Naidenko O, Miyake S, Yamamura T, Berberich I, Cardell S, Kronenberg M, Herrmann T. Pyz E, et al. J Immunol. 2006 Jun 15;176(12):7447-55. doi: 10.4049/jimmunol.176.12.7447. J Immunol. 2006. PMID: 16751390 - CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor.
Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, Koh R, Besra GS, Bharadwaj M, Godfrey DI, McCluskey J, Rossjohn J. Borg NA, et al. Nature. 2007 Jul 5;448(7149):44-9. doi: 10.1038/nature05907. Epub 2007 Jun 20. Nature. 2007. PMID: 17581592 - Regulation of immune responses by CD1d-restricted natural killer T cells.
Van Kaer L. Van Kaer L. Immunol Res. 2004;30(2):139-53. doi: 10.1385/IR:30:2:139. Immunol Res. 2004. PMID: 15477656 Review. - Antigen specificity of semi-invariant CD1d-restricted T cell receptors: the best of both worlds?
Gumperz JE. Gumperz JE. Immunol Cell Biol. 2004 Jun;82(3):285-94. doi: 10.1111/j.0818-9641.2004.01257.x. Immunol Cell Biol. 2004. PMID: 15186260 Review.
Cited by
- Thymic development of human natural killer T cells: recent advances and implications for immunotherapy.
Pellicci DG, Tavakolinia N, Perriman L, Berzins SP, Menne C. Pellicci DG, et al. Front Immunol. 2024 Aug 29;15:1441634. doi: 10.3389/fimmu.2024.1441634. eCollection 2024. Front Immunol. 2024. PMID: 39267746 Free PMC article. Review. - Traversing the bench to bedside journey for iNKT cell therapies.
O'Neal J, Mavers M, Jayasinghe RG, DiPersio JF. O'Neal J, et al. Front Immunol. 2024 Aug 7;15:1436968. doi: 10.3389/fimmu.2024.1436968. eCollection 2024. Front Immunol. 2024. PMID: 39170618 Free PMC article. Review. - Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
Nelson A, McMullen N, Gebremeskel S, De Antueno R, Mackenzie D, Duncan R, Johnston B. Nelson A, et al. Breast Cancer Res. 2024 May 15;26(1):78. doi: 10.1186/s13058-024-01818-5. Breast Cancer Res. 2024. PMID: 38750591 Free PMC article. - Natural killer T cells in allergic asthma: implications for the development of novel immunotherapeutical strategies.
Gutiérrez-Vera C, García-Betancourt R, Palacios PA, Müller M, Montero DA, Verdugo C, Ortiz F, Simon F, Kalergis AM, González PA, Saavedra-Avila NA, Porcelli SA, Carreño LJ. Gutiérrez-Vera C, et al. Front Immunol. 2024 Apr 2;15:1364774. doi: 10.3389/fimmu.2024.1364774. eCollection 2024. Front Immunol. 2024. PMID: 38629075 Free PMC article. Review. - T Cell Receptor-Engaging Monoclonal Antibodies Mobilize the Anti-Tumor Functions of Invariant Natural Killer T Cells.
Das R. Das R. Crit Rev Oncog. 2024;29(1):69-81. doi: 10.1615/CritRevOncog.2023049947. Crit Rev Oncog. 2024. PMID: 38421715
References
- Calabi F., Jarvis J.M., Martin L.H., Milstein C. Two classes of CD1 genes. Eur. J. Immunol. 1989;19:285–292. - PubMed
- Porcelli S.A., Modlin R.L. The CD1 systemantigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 1999;17:297–329. - PubMed
- Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science. 1997;278:1626–1629. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials